{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T05:36:18Z","timestamp":1792215378249,"version":"4.4.0"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[1995,7,1]],"date-time":"1995-07-01T00:00:00Z","timestamp":804556800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[1995,7,1]]},"abstract":"<jats:title>Abstarct<\/jats:title>\n                  <jats:p>The clinical efficacy and safety of enalapril were evaluated in dogs with moderate or severe heart failure. This study was conducted at 19 centers and included 211 clientowned dogs with heart failure caused by mitral regurgitation (MR) due to acquired valvular disease or dilated cardiomyopathy (DCM). Dogs of various breeds, ages, and weights were included in the study. Replicates of 2 dogs each were formed, using separate allocation schedules for dogs with MR or DCM. One dog within each replicate received placebo tablets (vehicle tablets without enalapril) PO sid or bid, and the other dog received enalapril tablets at approximately 0.5 mg\/kg sid or bid, based on individual need. In addition to the experimental drug, all dogs, except 1 in the placebo group, received furosemide; 73.3% of the dogs in the placebo group and 78.3% of those in the enala pril group received digoxin. Doses of enalapril or placebo were administered for approximately 28 days. In the placebo group, 68.6% of the dogs completed the study compared with 84.9% in the enalapril group; the difference between groups was significant (P= .01). Significantly (P= .01) more dogs in the placebo group compared with the enalapril group died or were removed from the study because of progression of heart failure. On day 28, all 14 clinical variables measured improved significantly (P= .01) in the enalapril group compared with the placebo group. Five dogs (3 from the placebo group and 2 from the enalapril group) had to be removed from the study as a result of azotemia.<\/jats:p>","DOI":"10.1111\/j.1939-1676.1995.tb01075.x","type":"journal-article","created":{"date-parts":[[2010,3,10]],"date-time":"2010-03-10T13:34:22Z","timestamp":1268228062000},"page":"243-252","source":"Crossref","is-referenced-by-count":109,"title":["Controlled Clinical Evaluation of Enalapril in Dogs With Heart Failure: Results of the Cooperative Veterinary Enalapril Study Group The COVE Study Group"],"prefix":"10.1093","volume":"9","author":[{"given":"Jerry A.","family":"Woodfield","sequence":"first","affiliation":[{"name":"Merck Research Laboratories, Merck and Co, Inc , Railway, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[1995,7,1]]},"reference":[{"key":"2026020303065732600_b1","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/0735-1097(92)90167-L","article-title":"The neurohormonal hypothesis: A theory to explain the mechanism of disease progression in heart failure","volume":"20","author":"Packer","year":"1992","journal-title":"J Am Coll Cardiol"},{"key":"2026020303065732600_b2","doi-asserted-by":"crossref","first-page":"3C","DOI":"10.1016\/0002-9149(93)90081-M","article-title":"How should physicians view heart failure? The philosophical and physiological evolution of three conceptual models of the disease","volume":"72","author":"Packer","year":"1993","journal-title":"Am J Cardiol"},{"key":"2026020303065732600_b3","doi-asserted-by":"crossref","first-page":"1D","DOI":"10.1016\/0002-9149(89)90408-6","article-title":"A symposium: Congestive heart failure-Advances in treatment","volume":"63","author":"Parmley","year":"1989","journal-title":"Am J Cardiol"},{"key":"2026020303065732600_b4","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJM199108013250508","article-title":"ACE inhibitors\u2014A cornerstone of the treatment of heart failure","volume":"325","author":"Braunwald","year":"1991","journal-title":"N Engl J Med"},{"key":"2026020303065732600_b5","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure","volume":"316","author":"Consensus Trial Study Group","year":"1987","journal-title":"N Engl J Med"},{"issue":"suppl 4","key":"2026020303065732600_b6","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2165\/00003495-199000394-00010","article-title":"Effect of enalapril on mortality in congestive heart failure. Follow-up survival data from the consensus trial","volume":"39","author":"Swedberg","year":"1990","journal-title":"Drugs"},{"key":"2026020303065732600_b7","doi-asserted-by":"crossref","first-page":"40D","DOI":"10.1016\/0002-9149(90)90475-G","article-title":"Effects of enalapril and neuroendocrine activation on prognosis in severe congestive heart failure (Follow-up of the consensus trial)","volume":"66","author":"Swedberg","year":"1990","journal-title":"Am J Cardiol"},{"issue":"suppl 3","key":"2026020303065732600_b8","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1097\/00005344-199000153-00002","article-title":"Enalapril in the treatment of congestive heart failure","volume":"15","author":"Giles","year":"1990","journal-title":"J Cardiovasc Pharmacol"},{"key":"2026020303065732600_b9","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","author":"SOLVD Investigators.","year":"1991","journal-title":"N Engl J Med"},{"key":"2026020303065732600_b10","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1056\/NEJM199108013250502","article-title":"A comparison of enalapril with hydralazine\u2014Isosorbide dinitrate in the treatment of chronic congestive heart failure","volume":"325","author":"Cohn","year":"1991","journal-title":"N Engl J Med"},{"key":"2026020303065732600_b11","first-page":"354","article-title":"Current concepts in vasodilator therapy for advanced or refractory congestive heart failure","volume":"29","author":"Miller","year":"1988","journal-title":"Can Vet J"},{"key":"2026020303065732600_b12","first-page":"309","volume-title":"Canine and Feline Cardiology","author":"Keene","year":"1988"},{"key":"2026020303065732600_b13","first-page":"319","volume-title":"Current Veterinary Therapy IX","author":"Bonagura","year":"1986"},{"key":"2026020303065732600_b14","first-page":"329","volume-title":"Current Veterinary Therapy IX","author":"Bonagura","year":"1986"},{"key":"2026020303065732600_b15","first-page":"334","volume-title":"Current Veterinary Therapy IX","author":"Knowlen","year":"1986"},{"key":"2026020303065732600_b16","first-page":"274","article-title":"Captopril: Is it the drug of choice in congestive heart failure? Proceedings of the Seventh Annual American College of Veterinary Internal Medicine Forum, San Diego, CA","author":"Tilley","year":"1989"},{"key":"2026020303065732600_b17","first-page":"295","article-title":"Cardiopulmonary Drugs I and II: Use and complications. Proceedings of the Seventh Annual American College of Veterinary Internal Medicine Forum, San Diego, CA","author":"Fox","year":"1989"},{"key":"2026020303065732600_b18","first-page":"231","volume-title":"Current Veterinary Therapy X","author":"Reed","year":"1989"},{"key":"2026020303065732600_b19","first-page":"240","volume-title":"Current Veterinary Therapy X","author":"Keene","year":"1989"},{"key":"2026020303065732600_b20","first-page":"467","volume-title":"Canine and Feline Cardiology","author":"Fox","year":"1988"},{"key":"2026020303065732600_b21","first-page":"773","volume-title":"Current Veterinary Therapy XI","author":"Calvert","year":"1992"},{"key":"2026020303065732600_b22","first-page":"713","volume-title":"Current Veterinary Therapy XI","author":"Rush","year":"1992"},{"key":"2026020303065732600_b23","first-page":"700","volume-title":"Current Veterinary Therapy XI","author":"DeLellis","year":"1992"},{"key":"2026020303065732600_b24","first-page":"939","volume-title":"Textbook of Veterinary Internal Medicine","author":"Keene","year":"1989","edition":"3rd"},{"key":"2026020303065732600_b25","first-page":"115","volume-title":"Manual of Small Animal Cardiology","author":"Tilley","year":"1985"},{"key":"2026020303065732600_b26","first-page":"171","volume-title":"Canine and Feline Cardiology","author":"Kittleson","year":"1988"},{"key":"2026020303065732600_b27","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1748-5827.1974.tb06529.x","article-title":"Observations on the effect of age on the severity of heart valve lesions in the dog","volume":"15","author":"Whitney","year":"1974","journal-title":"J Small Animal Pract"},{"key":"2026020303065732600_b28","first-page":"647","volume-title":"Current Veterinary Therapy XI","author":"Buchanan","year":"1992"},{"key":"2026020303065732600_b29","first-page":"81","article-title":"Epidemiological survey of dilatative cardiomyopathy in dogs","volume":"2","author":"Fioretti","year":"1988","journal-title":"Veterinaria"},{"key":"2026020303065732600_b30","first-page":"844","volume-title":"Textbook of Veterinary Internal Medicine","author":"Knight","year":"1995","edition":"4th"},{"key":"2026020303065732600_b31","first-page":"167","volume-title":"Analysis of Ordinal Categorical Data","author":"Agresti","year":"1984"},{"key":"2026020303065732600_b32","first-page":"986","volume-title":"SAS\/STAT User's Guide, Version 6","year":"1989","edition":"4th"},{"key":"2026020303065732600_b33","first-page":"125","volume-title":"Statistical Methods","author":"Snedecor","year":"1967","edition":"6th"},{"key":"2026020303065732600_b34","first-page":"124","article-title":"Titration of enalapril dose for dogs with induced heart failure","volume":"5","author":"Benitz","year":"1991","journal-title":"J Vet Intern Med"},{"key":"2026020303065732600_b35","doi-asserted-by":"crossref","first-page":"119C","DOI":"10.1016\/0002-9149(92)91369-F","article-title":"Angiotensin converting enzyme inhibitors and renal function in heart failure","volume":"70","author":"Dietz","year":"1992","journal-title":"Am J Cardiol"}],"container-title":["Journal of Veterinary Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1939-1676.1995.tb01075.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/9\/4\/243\/66682709\/j.1939-1676.1995.tb01075.x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/9\/4\/243\/66682709\/j.1939-1676.1995.tb01075.x.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T08:07:24Z","timestamp":1770106044000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jvim\/article\/9\/4\/243\/8451475"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1995,7,1]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1995,7,1]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1939-1676.1995.tb01075.x","relation":{},"ISSN":["1939-1676"],"issn-type":[{"value":"1939-1676","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[1995,7]]},"published":{"date-parts":[[1995,7,1]]}}}